Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio Presents New Iclaprim Data at ECCMID 2019|
April 16, 2019
|Motif Bio Reports Fiscal Year 2018 Results|
April 15, 2019
|Motif Bio to Present Iclaprim Data at ECCMID 2019|
April 4, 2019